Decreased Cord-Blood Phospholipids in Young Age–at–Onset Type 1 Diabetes
Abstract
Children developing type 1 diabetes may have risk markers already in their umbilical cord blood. It is hypothesized that the risk for type 1 diabetes at an early age may be increased by a pathogenic pregnancy and be reflected in altered cord-blood composition. This study used metabolomics to test if the cord-blood lipidome was affected in children diagnosed with type 1 diabetes before 8 years of age. The present case-control study of 76 index children diagnosed with type 1 diabetes before 8 years of age and 76 healthy control subjects matched for HLA risk, sex, and date of birth, as well as the mother’s age and gestational age, revealed that cord-blood phosphatidylcholines and phosphatidylethanolamines were significantly decreased in children diagnosed with type 1 diabetes before 4 years of age. Reduced levels of triglycerides correlated to gestational age in index and control children and to age at diagnosis only in the index children. Finally, gestational infection during the first trimester was associated with lower cord-blood total lysophosphatidylcholines in index and control children. In conclusion, metabolomics of umbilical cord blood may identify children at increased risk for type 1 diabetes. Low phospholipid levels at birth may represent key mediators of the immune system and contribute to early induction of islet autoimmunity.
Type 1 diabetes is one of the most common chronic diseases among children and adolescents, with a worldwide increase in incidence (1,2). The clinical onset occurs when insulin secretion decreases due to autoimmune destruction of β-cells. Often overlooked is a prodrome of islet autoimmunity manifested by autoantibodies toward the islet autoantigens insulin, GAD65, islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8) (3–6). Type 1 diabetes is also strongly associated with specific HLA-DQ haplotypes (7).
Factors triggering the onset of islet autoimmunity and the subsequent transition to overt diabetes are largely unknown, thus making a prevention strategy still a challenge. A critical role of the environment, including gestational, perinatal, and postnatal factors, cannot be excluded (8). It is known that gestational events might increase disease risk for the offspring (9), including type 1 diabetes (10,11) and celiac disease (12). It is hypothesized that the risk for type 1 diabetes at an early age might be increased by a pathogenic pregnancy and be reflected in altered cord-blood composition. It is therefore critical to identify biomarkers of type 1 diabetes risk as early as possible in life.
Global profiling of serum metabolites has been used to dissect clinical and pathogenic aspects of the progression to islet autoimmunity and type 1 diabetes (13–15). Metabolomics analysis of samples from children in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study diagnosed with type 1 diabetes at 0.5–13.5 years of age (14) showed that serum metabolites may mark progression to islet autoimmunity and from islet autoimmunity to diabetes. In that study (14), umbilical cord-blood levels of phosphatidylcholines (PCs) were reduced in children who developed diabetes compared with healthy autoantibody-negative children matched for HLA (14). This observation supports the notion that children exposed to gestational events may have increased risk for type 1 diabetes (16). More recently and independent of the present investigation, low cord-blood content of choline-containing phospholipids (PLs) was associated with progression to diabetes (17). In the Diabetes Prediction in Skåne (DiPiS) study, we found that gestational events affect birth weight and length (18) as well as the appearance of islet autoantibodies (19). We therefore analyzed umbilical cord serum by lipidomics (20,21) to test the hypothesis that a specific molecular lipid profile predicts type 1 diabetes.
The DiPiS study is a population-based study of a cohort of more than 35,000 children (17,22,23). We compared 76 DiPiS children who developed type 1 diabetes before 8 years of age with 76 control subjects matched for HLA, sex, date of birth, and the mother’s age. In this group of 152 children, we also analyzed the cord-blood lipidomic profile in relation to gestational events reported by the parents in clinical questionnaires (18).
RESEARCH DESIGN AND METHODS
Population and study design.
The DiPiS study was initiated in the Skåne region of Southern Sweden between September 2000 and August 2004. Umbilical cord-blood samples were collected from more than 35,000 newborns (24) and analyzed for HLA genotypes and islet autoantibodies (Fig. 1) (17,22). DiPiS children at increased risk for type 1 diabetes and islet autoantibody appearance have been analyzed every 4–12 months, depending on the number of islet autoantibodies. Gestational and perinatal events were reported by ∼25,000 parents in a questionnaire administered at the second postnatal visit (18).
Flowchart of study design. Index and control children were selected from a population-based newborn screening study (DiPiS study) between 2000 and 2004. Ab, autoantibody.
Until April 2010, when the first sample selection was initiated, 112 children had developed type 1 diabetes (Fig. 1). Twins/triplets, children born to diabetic (any type) mothers, and children positive for islet autoantibodies in the cord blood were not included in this study (Fig. 1). The suitable control children had not developed persistent islet autoantibodies or type 1 diabetes by April 2010. The case-control matching was based on date of birth (difference, 0–27 days), sample storage time, HLA, sex, the mother’s age, and gestational age. The study population consisted of 76 index children (40 boys) diagnosed with type 1 diabetes and 76 control children. The median age at diagnosis was 4.5 years (range 10 months–8 years). Index and control children did not differ in birth weight (P = 0.88) and length (P = 0.76), whereas index children (39.0 ± 1.7 weeks) showed slightly shorter gestational age than the control children (39.2 ± 1.3 weeks; P = 0.046) (Table 1). Retrospective questionnaires were available for 101 children, including 55 index and 46 control children, and reported information on the newborn (birth weight and length, jaundice) and gestational events (infections, vaccinations, diet, drugs, weight gain).
Baseline characteristics of index and control children
The study was approved by the Regional Ethics Board (2009/244), and parents gave informed consent when the child was 2 months of age.
Lipidomics analysis.
The samples were blinded, prepared, and analyzed in random order in duplicates with ultra–high-performance liquid chromatography combined with mass spectrometry (MS) (20). MS analysis was performed with electrospray ionization in the positive ion mode.
Data processing, detection and alignment of peaks, and peak integration and normalization were performed as already described in detail (14). Lipid identification was carried out through an in-house reference compound library or the MS/MS spectrum (20). Only identified lipids were included in the final dataset. The established lipidomics platform applied in this study covers the major lipid classes found in serum, including PCs, sphingomyelins (SMs), phosphatidylethanolamines (PEs), ceramides, and triglycerides (TGs).
Metabolite stability.
All samples were stored in the same place for 6.1–9.9 years at −20°C. The strict case-control matching for date of birth implies that each matched case-control pair has been stored for the same time and has undergone approximately the same number of freeze–thaw cycles. The concentration of the most abundant lysophospholipid (lysophosphatidylcholine [LPC] 16:0) was not affected by storage (R2 linear 0.008, P = 0.1), whereas the PCs PC(40:5), PC(40:7), PC(38:4), PC(38:5), PC(38:5e), PC(36:4), and PC(36:5e)/PE(38:5e) decreased significantly with increasing sample storage time (Supplementary Fig. 1).
Statistical analysis.
The index child 117 was a strong outlier (Grubbs’ procedure, P < 0.005, and the multivariate Hotelling’s T2 range plot) and excluded from further analysis along with the matched control.
Multivariate data analysis was performed on 150 samples by SIMCA-P+ 12.0 statistical software (Umetrics, Umeå, Sweden). Multivariate methods appear to be a valid tool for the analysis of complex and interdependent variables requiring multiple adjusting. The data were centered, Pareto-scaled to reduce the influence of noisy variables on the modeling results, and analyzed through projections methods as principal component analysis (PCA) and orthogonal partial least squares projections to latent structures discriminant analysis (OPLS-DA). PCA reduced the complexity of multidimensional datasets, creating low-dimensional coordinates from the principal determinants of the data variance. OPLS divided the data into related (predictive) and unrelated to a preset outcome and was applied to correlate the metabolite pattern with type 1 diabetes development, clinical features, and sample storage time. The data were evaluated through S-plots and shared and unique structure (SUS)-like plots for the identification of metabolic biomarkers (25). Additional statistical analysis was done with SPSS 18.0 software (PASW 18 Inc., Chicago, IL) with P < 0.05 considered significant. Case-control differences were calculated with parametric or nonparametric matched-pair tests, as appropriate. To account for false discovery rate in multiple comparisons (26), q values were calculated with the q-Value Calculator (statistical software R). The correlation between metabolite levels and storage duration or clinical features was evaluated through the Spearman ρ nonparametric correlation.
RESULTS
Metabolites detected in cord-blood samples.
A total of 106 lipid metabolites were identified in the cord-blood samples of the 152 children, including PLs (PCs, PEs, SMs, and LPCs/lyso phosphatidylethanolamines [LPEs]) and TGs (Table 2). First, a PCA of the whole dataset was performed, yielding an estimated predictive ability of 60% (Q2× = 0.6). The related loading plot showed that the lipid class was the strongest determinant of metabolite distribution (data not shown). Consistently, the levels of total PCs (PCtot), LPCs (LPCtot), PEs (PEtot), and SMs (SMtot) were strongly interrelated (P < 0.001 Spearman’s ρ) in index and control children. LPCtot (P = 0.02) and SMtot (P = 0.03) were also related to total TGs (TGtot).
Metabolites identified in cord-blood samples
Multivariate analysis of cord-blood lipidome data.
Second, models were calculated to compare case-control lipidomics pattern in relation to the age of type 1 diabetes diagnosis. The best predictive model for type 1 diabetes was achieved in children younger than 2 years of age at diagnosis, where PCs, PEs, and TGs explained 41% of the case-control separation (n = 18 observations; OPLS A 1 + 0 + 0; goodness of separation [R2Ycum], 32%; goodness of prediction [Q2cum], 16%). The groups of children older than 4 years at diagnosis could not be modeled.
Then, S-plots were used to identify metabolic markers of age at diagnosis. Cord-blood PCs were significantly lower in children developing type 1 diabetes before 4 years of age than in matched controls (85% negative correlation between PCtot and type 1 diabetes) (Supplementary Fig. 2A). Among children diagnosed before 2 years of age, low TGs were a better marker than PCs (0.95 negative correlation between TGtot and type 1 diabetes) (Supplementary Fig. 2B). The 3-year-olds did not differ from the 4-year-olds (data not shown). A SUS-like plot comparing children diagnosed before 2 and at 2–4 years of age (Supplementary Fig. 3) confirmed that low PLs (PCs, PEs, and SMs) marked type 1 diabetes in all children diagnosed when younger than 4 years of age, although reduced TGs showed a better predictive value in children diagnosed when younger than 2 years (Supplementary Fig. 3).
Additional analysis of cord-blood lipidome data.
Pairwise case-control analysis showed that median cord-blood levels of 50 of 58 PLs (PCs, PEs, and SMs) but only of 7 of 36 TGs were reduced in children diagnosed before 4 years of age compared with their matched controls (significant PC[36:4], P = 0.02; and PE[36:0], P = 0.02). Stepwise analysis of the index children showed that median cord-blood levels of 39 of 44 PCs/PEs were reduced in children diagnosed before 4 years of age compared with index children diagnosed when older than 4 years, and of these, 18 different lipids reached statistical significance (Table 3 and Supplementary Fig. 4). Interestingly, the matched controls did not show the same trend (Table 3 and Supplementary Fig. 4). A test on all age classes (10 months–8 years) confirmed that several PCs and PEs were significantly decreased in the cord blood of index children with younger age at onset (Table 3). Finally, as suggested by the multivariate plots (Supplementary Figs. 2 and 3), children diagnosed before 4 years of age showed lower levels of 34 of 36 TGs than matched controls, and 7 of these lipids reached statistical significance. However, cord-blood TGs decreased significantly with decreasing gestational age (P = 0.001, Kruskal-Wallis test). Cord-blood TGs and gestational age appeared more strongly correlated in index children (P = 0.007) than in control children (P = 0.049; Supplementary Fig. 5A). Moreover, gestational age was significantly related to the age at onset (P = 0.02). The S-plot for biomarkers of gestational age (Supplementary Fig. 5B) confirmed that TGs strongly increased with increasing gestational age, whereas PLs (PCs, PEs, and SMs) showed a weak, negative correlation with gestational age (Supplementary Fig. 5B).
PLs differing between children who developed diabetes before and after 4 years of age
Gestational infections, gestational age, and sex differences.
A total of 112 mothers reported gestational infections. Only 9 of 54 index children (16.6%) but 21 of 58 control children (36.2%) had a mother reporting gestational infection in the first trimester (P = 0.02). Among children diagnosed before 4 years of age, 5 of 19 (26%) had a mother reporting gestational infection during the first trimester, compared with 8 of 23 matched control children (34%) (P = 0.7). Among children diagnosed when older than 4 years of age, only 3 of 33 (9%) had a mother reporting a gestational infection during the first trimester, compared with 13 of 34 control children (38%) (P = 0.009). Lower levels of cord-blood LPCs were observed in index and control children (n = 112) born to mothers reporting a gestational infection (P = 0.04).
Male children (50.9 ± 2.3 cm) were taller at birth than female children (49.7 ± 1.8 cm; P = 0.03, controlling for gestational age). Index female children had shorter gestational age than female control children (P = 0.01) or index male children (P = 0.005). Index female children also showed significantly higher levels of 8 of 10 LPCs/PEs than female control children or index male children. Finally, we also observed that low TGs marked neonatal jaundice (90% positive correlation among 150 children, data not shown), as expected by the significantly shorter gestational age of children presenting with jaundice (index children, P = 0.003; controls, P < 0.001).
DISCUSSION
Our study of cord-blood lipidomics demonstrates that low levels of PCs and PEs increased the risk for type 1 diabetes diagnosed before 4 years of age. This finding may be of clinical relevance because epidemiological studies indicate that children diagnosed with type 1 diabetes at a young age are increasing. The importance of gestational events for disease risk in the offspring has been reviewed elsewhere (9,11,12,24). Altered cord-blood lipoproteins were reported in pathological conditions, such as intrauterine growth restriction and eclampsia, known to confer cardiovascular disease risk for the offspring (27). It would be of general importance to identify metabolite patterns that would distinguish the risk for different diseases in the offspring.
We tested the hypothesis that the lipidomic profile at birth might predict type 1 diabetes later in life. Fetal and neonatal serum lipids are markedly altered in women with maternal diabetes (28,29) but may be minimally affected by maternal lipids in normal pregnancies (28). Therefore, we excluded any type of maternal diabetes from the study (Fig. 1).
First, our study supports the recent observation of low cord-blood PC levels in 39 Finnish DIPP children who progressed to type 1 diabetes (14). We now extend this report to 75 Swedish children who developed type 1 diabetes before 8 years of age and 75 healthy and autoantibody-negative control children matched for HLA risk, sex, and date of birth (Fig. 1). Our major finding was that children developing type 1 diabetes before 4 years of age showed low levels of 50 different PLs, mainly PCs (Supplementary Figs. 2A and 4). Because PCs are the main source of choline, together with diet intake (30), it is possible to postulate that DiPiS children who will develop type 1 diabetes might be choline-deficient at birth (14). Also, an imbalance in the maternal diet during pregnancy might possibly influence fetal/neonatal availability of choline (30). Low-level PCs may have a role in an imbalanced oxidative stress, because PCs are thought to have anti-inflammatory properties (31).
The second result was that cord-blood levels of TGs were low in children diagnosed before 2 years of age (Supplementary Fig. 2B). The finding that TGs were strongly related to gestational age complicated this observation, because the very young children showed a significantly shorter gestational age (P = 0.02) than children diagnosed when older than 6 years of age. Thus, low-level TGs may not represent a risk factor for type 1 diabetes. In normal pregnancies, the main source of fetal TGs is de novo synthesis by the liver (32). However, cord-blood TG levels may partly reflect maternal hypertriglyceridemia in late pregnancy (28). The observed direct correlation between cord-blood TG levels and gestational age (Supplementary Fig. 5), already reported in normal pregnancies (33), is probably physiological and unrelated to any gestational event conferring type 1 diabetes risk in the offspring but is of possible significance for any disorder related to short gestational age. Indeed, several clinical conditions are reported related to short gestational age, including type 1 (34) and type 2 diabetes (35). In the entire DiPiS study (18), index children have significantly shorter gestational age than control children (P < 0.001). Our observation that age at diagnosis was related to gestational age was surprising but may be because all children were diagnosed when younger than 8 years of age.
Taken together, short gestational age, perhaps in combination with reduced TG levels, may confer risk for type 1 diabetes at very early ages (<2 years). This subgroup of very young children may explain the significant clinical heterogeneity in relation to age at diagnosis reported in type 1 diabetes (36). Further metabolomics studies are needed (37) to disclose whether cord-blood TG levels are more important than gestational age per se. We note in this respect that PC levels, inversely related to gestational age (Supplementary Fig. 5B), were still reduced in the children diagnosed before 4 years of age (Supplementary Figs. 2A and 3). Low PC levels therefore remain the best marker for type 1 diabetes in children younger than 4 years of age because TG levels were influenced by gestational age, especially among the index children.
Because the samples were taken at birth, that no markers for type 1 diabetes risk were found for children with later onset may not be surprising. Future investigation will be needed to determine at regular follow-up visits to what extent low PCs combined with serum C-peptide measurements can be used in prevention clinical studies. In the DIPP study, as recently reported (17) after an analysis carried out independent of and in parallel to the current study, seven lipids were identified that predicted high risk for progression to type 1 diabetes. Reduction in choline-containing PLs in cord blood was specifically associated with progression to type 1 diabetes. In addition, our observation that LPC/PE levels were significantly increased in female index children, regardless of age at onset, may suggest the presence of an imbalance of oxidative environment (38). Finally, the low level of LPCs that was found to be related to gestational infections would be consistent with the hypothesis of a decreased LPC content in patients with infective conditions (39).
We could not reinvestigate the effect of maternal age at delivery, a reported risk factor for type 1 diabetes in the offspring (40), because our case-control pairs were matched for the mother’s age to limit the influence of maternal metabolome.
A potential weakness of the study is the retrospective analysis of samples stored for a long time and of retrospective questionnaires collected by mothers after the delivery. The issue of metabolite stability is crucial for metabolomics evaluation because of the potential confounding effects of nonenzymatic lipid oxidation during long storage at suboptimal temperature. In this study, however, the stringent case-control matching controlled for metabolite stability and made it possible to conclude with a grade of confidence that observed metabolite variations were not due to storage. Our report on possible storage effects on metabolite concentration is of interest because no data have been published on samples stored more than a few weeks (41).
In conclusion, cord-blood metabolic patterns, rather than single metabolites, may be a valuable measure of type 1 diabetes risk. It may be important to include essentially all phospholipidic moieties in studies aimed at dissecting gestational events conferring disease risk in the offspring. Longitudinal studies of mothers from the first trimester until delivery will be important to disclose the character of gestational events that may lower cord-blood LPCs or affect TG levels in relation to the development of islet autoimmunity and diabetes in the offspring.
ACKNOWLEDGMENTS
The study was partly supported by the Swedish Research Council, including a Linné grant to Lund University Diabetes Centre, an equipment grant from the Knut and Alice Wallenberg Foundation, the European Union 7th Framework Programme: DIAPREPP (Diabetes type 1 Prediction, Early Pathogenesis and Prevention, grant agreement 202013), the Swedish Diabetes Association Research Fund, the Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012-2017, Decision No. 250114), the Childhood Diabetes Foundation, and the Skåne County Council for Research and Development, as well as the UMAS Funds.
No potential conflicts of interest relevant to this article were reported.
D.L.T. designed the study, analyzed and researched data, and wrote the manuscript. T.S-L., H.E.L., T.H., S.A.I., and Å.L. designed the study, researched data, contributed to discussion, and reviewed and edited the manuscript. M.O. was responsible for the lipidomics analysis, analyzed data, contributed to discussion, and reviewed and edited the manuscript. D.L.T. and M.O. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
The authors thank Ida Jönsson, Anita Nilsson, Ali Shalouie, and Annika Winqvist (Department of Clinical Sciences, Lund University CRC, Skåne University Hospital [SUS], Malmö, Sweden) for expert technical assistance, and the participating parents and children in the DiPiS study. The authors thank Annelie Carlsson, Department of Pediatrics, Lund University Hospital, Malmö, Sweden; Elisabeth Cederwall, Department of Pediatrics, Ängelholm Hospital, Ängelholm, Sweden; Björn Jönsson, Department of Pediatrics, Ystad Hospital, Ystad, Sweden; Karin Larsson, Department of Pediatrics, Kristianstad Hospital, Kristianstad, Sweden; and Jan Neiderud, Department of Pediatrics, Helsingborg Hospital, Helsingborg, Sweden, all of the DiPiS Study Group.
Footnotes
* A complete list of the DiPiS Study Group can be found in the Acknowledgments.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0215/-/DC1.
- Received February 6, 2013.
- Accepted August 1, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
REFERENCES
In this Issue
